156 related articles for article (PubMed ID: 21961483)
1. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.
Yuan MK; Chang CY; Chang SC; Chang SJ; Tang GJ; Wei YF; Liu YC; Chen CY; Yu CJ
Int J Clin Pharmacol Ther; 2011 Oct; 49(10):587-93. PubMed ID: 21961483
[TBL] [Abstract][Full Text] [Related]
2. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
Endo M; Johkoh T; Kimura K; Yamamoto N
Lung Cancer; 2006 May; 52(2):135-40. PubMed ID: 16574271
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
4. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
Naito Y; Tsuchiya S; Ishihara S; Minato K; Shitara Y; Takise A; Suga T; Mogi A; Yamabe K; Saito R
Am J Clin Oncol; 2008 Aug; 31(4):340-4. PubMed ID: 18845992
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Chang SC; Chang CY; Chang SJ; Yuan MK; Lai YC; Liu YC; Chen CY; Kuo LC; Yu CJ
Clin Lung Cancer; 2013 Jan; 14(1):55-61. PubMed ID: 22607779
[TBL] [Abstract][Full Text] [Related]
6. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease associated with gefitinib.
Kataoka K; Taniguchi H; Hasegawa Y; Kondoh Y; Kimura T; Nishiyama O; Imaizumi K; Kawabe T; Kume H; Shimokata K
Respir Med; 2006 Apr; 100(4):698-704. PubMed ID: 16137874
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
Beom SH; Kim DW; Sim SH; Keam B; Park JH; Lee JO; Kim TM; Lee SH; Heo DS
Cancer Res Treat; 2016 Jan; 48(1):88-97. PubMed ID: 25761482
[TBL] [Abstract][Full Text] [Related]
10. Recurrent gefitinib-induced interstitial lung disease.
Suzuki M; Asahina H; Konishi J; Yamazaki K; Nishimura M
Intern Med; 2008; 47(6):533-6. PubMed ID: 18344641
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Kudoh S; Kato H; Nishiwaki Y; Fukuoka M; Nakata K; Ichinose Y; Tsuboi M; Yokota S; Nakagawa K; Suga M; ; Jiang H; Itoh Y; Armour A; Watkins C; Higenbottam T; Nyberg F
Am J Respir Crit Care Med; 2008 Jun; 177(12):1348-57. PubMed ID: 18337594
[TBL] [Abstract][Full Text] [Related]
12. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
13. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.
Hotta K; Kiura K; Tabata M; Harita S; Gemba K; Yonei T; Bessho A; Maeda T; Moritaka T; Shibayama T; Matsuo K; Kato K; Kanehiro A; Tanimoto Y; Matsuo K; Ueoka H; Tanimoto M
Cancer J; 2005; 11(5):417-24. PubMed ID: 16259873
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib: an adverse effects profile.
Cersosimo RJ
Expert Opin Drug Saf; 2006 May; 5(3):469-79. PubMed ID: 16610973
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.
Kitajima H; Takahashi H; Harada K; Kanai A; Inomata S; Taniguchi H; Saikai T; Abe S
Respirology; 2006 Mar; 11(2):217-20. PubMed ID: 16548909
[TBL] [Abstract][Full Text] [Related]
18. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.
Tsuboi M; Kato H; Nagai K; Tsuchiya R; Wada H; Tada H; Ichinose Y; Fukuoka M; Jiang H
Anticancer Drugs; 2005 Nov; 16(10):1123-8. PubMed ID: 16222155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
